Small-sample behavior of novel phase I cancer trial designs.

@article{Oron2013SmallsampleBO,
  title={Small-sample behavior of novel phase I cancer trial designs.},
  author={Assaf P. Oron and Peter D. Hoff},
  journal={Clinical trials},
  year={2013},
  volume={10 1},
  pages={
          63-80
        }
}
BACKGROUND Novel dose-finding designs for Phase I cancer clinical trials, using estimation to assign the best estimated Maximum Tolerated Dose (MTD) at each point in the experiment, most prominently via Bayesian techniques, have been widely discussed and promoted since 1990. PURPOSE To examine the small-sample behavior of these 'Bayesian Phase I' designs, and also of non-Bayesian designs sharing the same main 'Long-Memory' traits of using likelihood estimation and assigning the estimated MTD… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM.

  • Journal of biopharmaceutical statistics
  • 2014
VIEW 3 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 51 REFERENCES

cancer using a continual reassessment method

B. Neuenschwander, M. Branson, T. Gsponer
  • Japan J Clin Oncol
  • 2008
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL

Model calibration in the continual reassessment method.

Shing M Lee, Ying Kuen Cheung
  • Clinical trials
  • 2009
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Design efficiency in dose finding studies

  • Computational Statistics & Data Analysis
  • 2004
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL